GlassScriptPhysician profile
Scott A Lewis
NPI 1609847714
$13,693.14
in general payments reported to CMS, 2019-2025
49 companies · $3,112 in 2025
The $3,112 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,832 · 2022: $2,471 · 2023: $2,297 · 2024: $2,980 · 2025: $3,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,656 · Travel and Lodging: $533 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,656.28 |
| Travel and Lodging | $533.05 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,561.03 | 2021-2025 | Erleada, Akeega, Carvykti |
| Sumitomo Pharma America, INC. | $1,251.13 | 2023-2025 | Gemtesa, Orgovyx |
| Axonics, INC. | $989.60 | 2021-2024 | Axonics |
| Astellas Pharma US INC | $972.19 | 2021-2025 | Xtandi, Veozah, Myrbetriq |
| Abbvie INC. | $832.93 | 2021-2025 | |
| Endo Pharmaceuticals INC. | $769.22 | 2021-2024 | Aveed, Xiaflex, Edex |
| Myriad Genetic Laboratories, INC. | $760.25 | 2021-2025 | Prolaris |
| Pfizer INC. | $755.61 | 2021-2025 | |
| Dendreon Pharmaceuticals LLC | $458.12 | 2022-2025 | Provenge |
| Ferring Pharmaceuticals INC. | $443.26 | 2024-2025 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $396.98 | 2021-2025 | |
| Amgen INC. | $385.75 | 2021-2024 | Prolia, Xgeva |
| Antares Pharma, INC. | $285.07 | 2021-2025 | Xyosted |
| Coloplast Corp | $263.85 | 2021-2024 | |
| Blue Earth Diagnostics | $239.21 | 2021-2024 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $238.08 | 2021-2022 | |
| Endo USA, INC. | $231.09 | 2024-2025 | Xiaflex, Aveed, Edex |
| Tolmar Pharmaceuticals, INC. | $210.18 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $206.06 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $192.49 | 2022-2025 | |
| Tolmar, INC. | $190.60 | 2023-2025 | Eligard, Jatenzo |
| Astrazeneca Pharmaceuticals LP | $174.56 | 2021-2023 | Lynparza |
| Boston Scientific Corporation | $157.12 | 2021-2025 | Axonics, Greenlight Xps, Advantage System |
| Allergan, INC. | $137.66 | 2021-2022 | |
| Accord Healthcare, INC. | $135.46 | 2023-2025 | |
| Urogen Pharma, INC. | $134.95 | 2021-2025 | Jelmyto |
| Clarus Therapeutics INC. | $127.72 | 2021 | |
| Verity Pharmaceuticals INC. | $118.00 | 2022-2025 | Trelstar |
| Sun Pharmaceutical Industries INC. | $113.35 | 2022-2025 | |
| Tempus Ai, INC | $100.69 | 2024-2025 | Xt Cdx |
| Seagen INC. | $99.99 | 2025 | |
| Novo Nordisk INC | $96.38 | 2021 | |
| Medtronic, INC. | $91.58 | 2022 | |
| Janssen Scientific Affairs, LLC | $79.37 | 2024 | Akeega, Erleada |
| Myovant Sciences INC. | $78.59 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $55.26 | 2024-2025 | |
| Caris Mpi, INC. | $51.05 | 2025 | Mi Cancer Seek |
| Telix Pharmaceuticals | $50.23 | 2022-2023 | Illuccix |
| Lsi Solutions INC | $39.90 | 2024 | Jnw Urtrac |
| Teleflex LLC | $35.21 | 2023 | Urolift |
| Ultragenyx Pharmaceutical INC. | $30.96 | 2022 | |
| Alexion Pharmaceuticals, INC. | $26.65 | 2022 | |
| Civco Medical Instruments | $22.81 | 2024 | |
| Immunitybio, INC. | $22.24 | 2024 | |
| Mimedx Group, INC. | $19.91 | 2024 | |
| Seqirus USA INC | $16.78 | 2021 | |
| Bioprotect Medical, INC. | $15.64 | 2025 | Bioprotect Balloon Implant System |
| Sagent Pharmaceuticals | $15.14 | 2024 | Glydo |
| Kowa Pharmaceuticals America, INC. | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.